Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times | Synapse
Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times
Key Points
Key points are not available for this paper at this time.
Abstract
The combination BBBM with MMSE is projected to increase the efficiency and value of the triage process for DMT eligibility.